Cargando…

RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates

The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. The ultimate approach to end the pandemic is the timely application of vaccines to achieve herd immunity. Here, a novel SARS-CoV-2 r...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Xiaoyan, Shi, Jian, Hu, Xue, Wu, Yan, Zeng, Liang, Yao, Yanfeng, Shang, Weijuan, Liu, Kunpeng, Gao, Ge, Guo, Weiwei, Peng, Yun, Chen, Shaohong, Gao, Xiaoxiao, Peng, Cheng, Rao, Juhong, Zhao, Jiaxuan, Gong, Cheng, Zhou, Hui, Lu, Yudong, Wang, Zili, Hu, Xiliang, Cong, WenJuan, Fang, Lijuan, Yan, Yongxiang, Zhang, Jing, Xiong, Hui, Yi, Jizu, Yuan, Zhiming, Zhou, Pengfei, Shan, Chao, Xiao, Gengfu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Singapore 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423076/
https://www.ncbi.nlm.nih.gov/pubmed/34493710
http://dx.doi.org/10.1038/s41421-021-00320-y
_version_ 1783749393243963392
author Pan, Xiaoyan
Shi, Jian
Hu, Xue
Wu, Yan
Zeng, Liang
Yao, Yanfeng
Shang, Weijuan
Liu, Kunpeng
Gao, Ge
Guo, Weiwei
Peng, Yun
Chen, Shaohong
Gao, Xiaoxiao
Peng, Cheng
Rao, Juhong
Zhao, Jiaxuan
Gong, Cheng
Zhou, Hui
Lu, Yudong
Wang, Zili
Hu, Xiliang
Cong, WenJuan
Fang, Lijuan
Yan, Yongxiang
Zhang, Jing
Xiong, Hui
Yi, Jizu
Yuan, Zhiming
Zhou, Pengfei
Shan, Chao
Xiao, Gengfu
author_facet Pan, Xiaoyan
Shi, Jian
Hu, Xue
Wu, Yan
Zeng, Liang
Yao, Yanfeng
Shang, Weijuan
Liu, Kunpeng
Gao, Ge
Guo, Weiwei
Peng, Yun
Chen, Shaohong
Gao, Xiaoxiao
Peng, Cheng
Rao, Juhong
Zhao, Jiaxuan
Gong, Cheng
Zhou, Hui
Lu, Yudong
Wang, Zili
Hu, Xiliang
Cong, WenJuan
Fang, Lijuan
Yan, Yongxiang
Zhang, Jing
Xiong, Hui
Yi, Jizu
Yuan, Zhiming
Zhou, Pengfei
Shan, Chao
Xiao, Gengfu
author_sort Pan, Xiaoyan
collection PubMed
description The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. The ultimate approach to end the pandemic is the timely application of vaccines to achieve herd immunity. Here, a novel SARS-CoV-2 receptor-binding domain (RBD) homodimer was developed as a SARS-CoV-2 vaccine candidate. Formulated with aluminum adjuvant, RBD dimer elicited strong immune response in both rodents and non-human primates, and protected mice from SARS-CoV-2 challenge with significantly reducing viral load and alleviating pathological injury in the lung. In the non-human primates, the vaccine could prevent majority of the animals from SARS-CoV-2 infection in the respiratory tract and reduce lung damage. In addition, antibodies elicited by this vaccine candidate showed cross-neutralization activities to SARS-CoV-2 variants. Furthermore, with our expression system, we provided a high-yield RBD homodimer vaccine without additional biosafety or special transport device supports. Thus, it may serve as a safe, effective, and low-cost SARS-CoV-2 vaccine candidate.
format Online
Article
Text
id pubmed-8423076
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Singapore
record_format MEDLINE/PubMed
spelling pubmed-84230762021-09-08 RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates Pan, Xiaoyan Shi, Jian Hu, Xue Wu, Yan Zeng, Liang Yao, Yanfeng Shang, Weijuan Liu, Kunpeng Gao, Ge Guo, Weiwei Peng, Yun Chen, Shaohong Gao, Xiaoxiao Peng, Cheng Rao, Juhong Zhao, Jiaxuan Gong, Cheng Zhou, Hui Lu, Yudong Wang, Zili Hu, Xiliang Cong, WenJuan Fang, Lijuan Yan, Yongxiang Zhang, Jing Xiong, Hui Yi, Jizu Yuan, Zhiming Zhou, Pengfei Shan, Chao Xiao, Gengfu Cell Discov Article The pandemic of COVID-19 caused by SARS-CoV-2 has raised a new challenges to the scientific and industrious fields after over 1-year spread across different countries. The ultimate approach to end the pandemic is the timely application of vaccines to achieve herd immunity. Here, a novel SARS-CoV-2 receptor-binding domain (RBD) homodimer was developed as a SARS-CoV-2 vaccine candidate. Formulated with aluminum adjuvant, RBD dimer elicited strong immune response in both rodents and non-human primates, and protected mice from SARS-CoV-2 challenge with significantly reducing viral load and alleviating pathological injury in the lung. In the non-human primates, the vaccine could prevent majority of the animals from SARS-CoV-2 infection in the respiratory tract and reduce lung damage. In addition, antibodies elicited by this vaccine candidate showed cross-neutralization activities to SARS-CoV-2 variants. Furthermore, with our expression system, we provided a high-yield RBD homodimer vaccine without additional biosafety or special transport device supports. Thus, it may serve as a safe, effective, and low-cost SARS-CoV-2 vaccine candidate. Springer Singapore 2021-09-07 /pmc/articles/PMC8423076/ /pubmed/34493710 http://dx.doi.org/10.1038/s41421-021-00320-y Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Pan, Xiaoyan
Shi, Jian
Hu, Xue
Wu, Yan
Zeng, Liang
Yao, Yanfeng
Shang, Weijuan
Liu, Kunpeng
Gao, Ge
Guo, Weiwei
Peng, Yun
Chen, Shaohong
Gao, Xiaoxiao
Peng, Cheng
Rao, Juhong
Zhao, Jiaxuan
Gong, Cheng
Zhou, Hui
Lu, Yudong
Wang, Zili
Hu, Xiliang
Cong, WenJuan
Fang, Lijuan
Yan, Yongxiang
Zhang, Jing
Xiong, Hui
Yi, Jizu
Yuan, Zhiming
Zhou, Pengfei
Shan, Chao
Xiao, Gengfu
RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates
title RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates
title_full RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates
title_fullStr RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates
title_full_unstemmed RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates
title_short RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates
title_sort rbd-homodimer, a covid-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423076/
https://www.ncbi.nlm.nih.gov/pubmed/34493710
http://dx.doi.org/10.1038/s41421-021-00320-y
work_keys_str_mv AT panxiaoyan rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT shijian rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT huxue rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT wuyan rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT zengliang rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT yaoyanfeng rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT shangweijuan rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT liukunpeng rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT gaoge rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT guoweiwei rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT pengyun rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT chenshaohong rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT gaoxiaoxiao rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT pengcheng rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT raojuhong rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT zhaojiaxuan rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT gongcheng rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT zhouhui rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT luyudong rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT wangzili rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT huxiliang rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT congwenjuan rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT fanglijuan rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT yanyongxiang rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT zhangjing rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT xionghui rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT yijizu rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT yuanzhiming rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT zhoupengfei rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT shanchao rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates
AT xiaogengfu rbdhomodimeracovid19subunitvaccinecandidateelicitsimmunogenicityandprotectioninrodentsandnonhumanprimates